版权说明 操作指南
首页 > 成果 > 详情

Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Deng, Wenying;Zhao, Zeyi;Zou, Tao;Kuang, Tongdong;Wang, Jing
通讯作者:
Wang, J;Kuang, TD
作者机构:
[Deng, Wenying; Wang, Jing; Zhao, Zeyi] Univ South China, Sch Basic Med Sci, Hengyang 421001, Hunan, Peoples R China.
[Zou, Tao] Univ South China, Affiliated Hosp 1, Dept Cardiovasc Med, Hengyang 421001, Hunan, Peoples R China.
[Kuang, Tongdong] Guilin Med Univ, Guangxi Key Lab Diabetic Syst Med, Guilin 541199, Guangxi, Peoples R China.
通讯机构:
[Kuang, TD ] G
[Wang, J ] U
Univ South China, Sch Basic Med Sci, Hengyang 421001, Hunan, Peoples R China.
Guilin Med Univ, Guangxi Key Lab Diabetic Syst Med, Guilin 541199, Guangxi, Peoples R China.
语种:
英文
关键词:
Fc protein;albumin;diabetes mellitus;fusion protein;glucagon-like peptide 1 receptor agonists;transferrin
期刊:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
ISSN:
1178-7007
年:
2024
卷:
17
页码:
343-362
基金类别:
Provincial Natural Science Foundation of Hunan [2019JJ50503, 2021JJ70121]; National College Students Research Study and Innovative Experiment Project [202110555100]
机构署名:
本校为第一且通讯机构
院系归属:
医学院
摘要:
Diabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels, resulting in multi-organ dysfunction and various complications. Fusion proteins can form multifunctional complexes by combining the target proteins with partner proteins. It has significant advantages in improving the performance of the target proteins, extending their biological half-life, and enhancing patient drug compliance. Fusion protein-based drugs have emerged as promising new drugs in diabetes therapeutics. However, there has not been a systematic review of fusion protein-based drugs ...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com